Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis
- PMID: 20624978
- PMCID: PMC2922129
- DOI: 10.1073/pnas.1007394107
Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis
Abstract
The programmed death-1 (PD-1) costimulatory receptor inhibits T and B cell responses and plays a crucial role in peripheral tolerance. PD-1 has recently been shown to inhibit T cell responses during chronic viral infections such as HIV. In this study, we examined the role of PD-1 in infection with Mycobacterium tuberculosis, a common co-infection with HIV. PD-1-deficient mice showed dramatically reduced survival compared with wild-type mice. The lungs of the PD-1-/- mice showed uncontrolled bacterial proliferation and focal necrotic areas with predominantly neutrophilic infiltrates, but a lower number of infiltrating T and B cells. Proinflammatory cytokines, such as TNF-alpha, IL-1, and especially IL-6 and IL-17 were significantly increased in the lung and sera of infected PD-1-/- mice, consistent with an aberrant inflammation. Microarray analysis of the lungs infected with M. tuberculosis showed dramatic differences between PD-1-/- and control mice. Using high-stringency analysis criteria (changes of twofold or greater), 367 transcripts of genes were differentially expressed between infected PD-1-/- and wild-type mice, resulting in profoundly altered inflammatory responses with implications for both innate and adaptive immunity. Overall, our studies show that the PD-1 pathway is required to control excessive inflammatory responses after M. tuberculosis infection in the lungs.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Comment in
-
PD1 turns down the heat.Nat Rev Microbiol. 2010 Sep;8(9):612. doi: 10.1038/nrmicro2430. Nat Rev Microbiol. 2010. PMID: 20737665 No abstract available.
Similar articles
-
Role of the CD137 ligand (CD137L) signaling pathway during Mycobacterium tuberculosis infection.Immunobiology. 2014 Jan;219(1):78-86. doi: 10.1016/j.imbio.2013.08.009. Epub 2013 Aug 23. Immunobiology. 2014. PMID: 24091276
-
Protective CD4 T cells targeting cryptic epitopes of Mycobacterium tuberculosis resist infection-driven terminal differentiation.J Immunol. 2014 Apr 1;192(7):3247-58. doi: 10.4049/jimmunol.1300283. Epub 2014 Feb 26. J Immunol. 2014. PMID: 24574499
-
T cells from Programmed Death-1 deficient mice respond poorly to Mycobacterium tuberculosis infection.PLoS One. 2011 May 12;6(5):e19864. doi: 10.1371/journal.pone.0019864. PLoS One. 2011. PMID: 21589883 Free PMC article.
-
TNF in host resistance to tuberculosis infection.Curr Dir Autoimmun. 2010;11:157-79. doi: 10.1159/000289204. Epub 2010 Feb 18. Curr Dir Autoimmun. 2010. PMID: 20173394 Review.
-
Interleukin-12 and tuberculosis: an old story revisited.Curr Opin Immunol. 2007 Aug;19(4):441-7. doi: 10.1016/j.coi.2007.07.004. Epub 2007 Aug 16. Curr Opin Immunol. 2007. PMID: 17702558 Free PMC article. Review.
Cited by
-
Active and latent tuberculosis infections in patients treated with immune checkpoint inhibitors in a non-endemic tuberculosis area.Cancer Immunol Immunother. 2021 Nov;70(11):3105-3111. doi: 10.1007/s00262-021-02905-8. Epub 2021 Mar 26. Cancer Immunol Immunother. 2021. PMID: 33770211 Free PMC article.
-
Reconsidering the Optimal Immune Response to Mycobacterium tuberculosis.Am J Respir Crit Care Med. 2020 Feb 15;201(4):407-413. doi: 10.1164/rccm.201908-1506PP. Am J Respir Crit Care Med. 2020. PMID: 31657633 Free PMC article. No abstract available.
-
T lymphocyte surface expression of exhaustion markers as biomarkers of the efficacy of chemotherapy for tuberculosis.Tuberculosis (Edinb). 2011 Jul;91(4):308-13. doi: 10.1016/j.tube.2011.04.001. Epub 2011 Apr 29. Tuberculosis (Edinb). 2011. PMID: 21530406 Free PMC article.
-
Assessment of anti-PD-(L)1 for patients with coexisting malignant tumor and tuberculosis classified by active, latent, and obsolete stage.BMC Med. 2021 Dec 20;19(1):322. doi: 10.1186/s12916-021-02194-z. BMC Med. 2021. PMID: 34923987 Free PMC article.
-
Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial.J Immunother Cancer. 2021 Aug;9(8):e002804. doi: 10.1136/jitc-2021-002804. J Immunother Cancer. 2021. PMID: 34446577 Free PMC article.
References
-
- McShane H. Co-infection with HIV and TB: Double trouble. Int J STD AIDS. 2005;16:95–100, quiz 101. - PubMed
-
- Flynn JL, et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity. 1995;2:561–572. - PubMed
-
- Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol. 2001;19:93–129. - PubMed
-
- Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23:515–548. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P01 AI063537/AI/NIAID NIH HHS/United States
- P30 AI051519/AI/NIAID NIH HHS/United States
- AI-51519/AI/NIAID NIH HHS/United States
- AI-07289/AI/NIAID NIH HHS/United States
- T32 AI007501/AI/NIAID NIH HHS/United States
- AI-26170/AI/NIAID NIH HHS/United States
- AI-063537/AI/NIAID NIH HHS/United States
- P30CA-013330/CA/NCI NIH HHS/United States
- R01 AI007289/AI/NIAID NIH HHS/United States
- P30 CA013330/CA/NCI NIH HHS/United States
- HHMI/Howard Hughes Medical Institute/United States
- R56 AI007289/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
